Clover Selected for Inclusion on the Hang Seng Composite Index

CHENGDU, China, Feb. 24, 2022 (GLOBE NEWSWIRE) --  Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022.

• Hang Seng Composite Index
• Hang Seng Small Cap (Investable) Index
• Hang Seng Healthcare Index
• Hang Seng Hong Kong-Listed Biotech Index
• Hang Seng Stock Connect Hong Kong Index
• Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index
• Hang Seng Stock Connect Hong Kong SmallCap Index
• Hang Seng SCHK Mainland China Companies Index
• Hang Seng SCHK ex-AH Companies Index
  

The Hang Seng Composite Index (“HSCI”) offers a comprehensive Hong Kong market benchmark that covers about 95% of the total market capitalization of companies listed on the Main Board. Inclusion on the HSCI will allow the company’s stock to be eligible for trading on the Hong Kong Stock Connect, a channel for stock trading between investors in Hong Kong and those in Mainland China.

“We are pleased to be added as a constituent stock on the Hang Seng Composite Index. Inclusion on the HSCI, a highly regarded index, will help facilitate the broadening of Clover’s shareholder base, increase trading liquidity and raise global awareness, which will be integral as we complete global regulatory filings for our COVID-19 vaccine candidate and advance our portfolio of innovative vaccine and oncology therapies,” stated Joshua Liang, Chief Executive Officer and Executive Director of Clover Biopharmaceuticals.

About SCB-2019 (CpG 1018/Alum)

SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidate, is anticipated to potentially be one of the first protein-based COVID-19 vaccines commercialized globally through the COVAX Facility. Employing the Trimer-Tag technology platform, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein (referred to as S-Trimer) based on the original strain of the SARS-CoV-2 virus. Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s (Nasdaq: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).